Donor lymphocyte infusions

Current Opinion in Oncology

Volumn 8, Issue 2, 1996, Pages 96-102

  Giralt, Sergio A ^a   Kolb, Hans Joachem ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CHRONIC MYELOID LEUKEMIA; HUMAN; HUMAN CELL; LYMPHOCYTE TRANSFER; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT INDICATION; TUMOR IMMUNOLOGY;

EID: 0029890197     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199603000-00004     Document Type: Review

References (61)

1. Slavin S, Ackerstein A, Weiss L, et al.: New therapeutic strategies for autologous and allogeneic bone marrow transplantation. Exp Hematol 1987, 15:595.
2. Kolb H, Beisser K, Holler E, et al.: Donor buffy coat transfusions for adoptive immunotherapy in human and canine chimeras. Periodicum Biolgorum 1991, 83:81.
3. Kolb H, Mittermuller J, Cleem C, et al.: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76:2462.
4. Porter D, Roth M, McGarigle C, Ferrara J, Antin J: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994, 330:100. Large single-institution series that characterizes the clinical course of donor lymphocyte infusions, response, and complications.
5. Bar B, Schattenberg A, Mensink E, et al.: Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 1993, 11:513. Single-institution series that characterizes the clinical course of donor lymphocyte infusions, response, and complications.
6. Helg C, Roux E, Beris P, et al.: Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 1993, 12:125.
7. Drobyski W, Keever C, Roth M, et al.: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993, 82:2310.
8. Hertenstein B, Wiesneth M, Novotny J, et al.: Interferon-α and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation 1993, 56:1114.
9. + cells/kg.
10. + cells/kg without antileukemic effect, suggesting different thresholds for antiviral effects and antileukemic effect.
11. van Rhee F, Lin F, Cullis J, et al.: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994, 83:3377. Donor lymphocyte infusions seem to be more effective and less toxic when done in cytogenetic relapse than in hematologic relapse. The results, however, should not be interpreted as a reason to use donor lymphocyte infusions in patients with isolated molecular relapses.
12. Giralt S, Hester J, Huh Y, et al.: CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: graft-vs-leukemia without graft-vs-host disease. Blood 1996, in press. CD8-depleted donor lymphocyte infusions are feasible and seem to be as effective as unmanipulated donor lymphocyte infusions. Randomized trials will be required to determine if CD8-depleted donor lymphocytes are associated with a lower risk of GVHD.
13. Kolb H, Schattenberg A, Goldman J, et al.: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86:2041. Largest published series on donor lymphocyte infusions for relapse after allogeneic BMT. Multivariate analysis for response and complications.
14. Townsend A, Rothbard J, Gutch F, et al.: The epitopes of influenza nucleoprotein recognized by cytotoxic T-lymphocytes can be defined with short synthetic peptides. Cell 1986, 44:959.
15. Brodsky F, Guaghardi L: The cell biology of antigen processing and presentation. Ann Rev Immunol 1991, 9:707.
16. Bjorkmen P, Saper M, Sauraoui B, et al.: The foreign antigen binding site and T-cell recognition regions of class 1 histocompatibility antigens. Nature 1987, 329:512.
17. Hull A, Allsopp C, Kwiatkowski P, et al.: Common West African HLA antigens are associated with protection from severe malaria. Nature 1991, 352:595.
18. Roy R, Sherer M, Briner T, et al.: Murine MHC polymorphism and T cell specificities. Science 1989, 244:572.
19. Restifo N, Esquivel F, Asher A, et al.: Defective presentation of endogenous antigens by a murine sarcoma: implications for the failure of an anti-tumor immune response. J Immunol 1991, 147:1453.
20. Townsend A, Bodner H: Antigen recognition by class I restricted T-lymphocytes. Ann Rev Immunol 1989, 17:601.
21. Nuchtern J, Biddison W, Klausner R: Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature 1990, 343:64.
22. Theobald M: Allorecognition and graft-versus-host disease. Bone Marrow Transplant 1995, 15:489. An excellent review. This paper summarizes the current knowledge regarding peptide processing and allo-recognition and implications for GVHD and graft-versus-leukemia.
23. Restifo N: Antigen processing and presentation: an update. Biologic Therapies of Cancer Updates 1992, 2:1-10.
24. Voogt P, Goulmy E, Veeuhof W, et al.: Cellularly defined minor histocompatibility antigens are differentially expressed on human hematopoietic progenitor cells. J Exp Med 1988, 168:2337.
25. Goulmy E, Pool J, Van den Elsen P: Interindividual conservation of T-cell receptor β chain variable regions by minor histocompatibility antigen-specific HLA-A* 0201-restricted cytotoxic T-cell clones. Blood 1995, 85:2478.
26. Den Haan J, Sherman N, Blokland E, et al.: Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995, 268:1476. This paper contains evidence that minor histocompatibility antigens are clinically relevant for GVHD.
27. Van der Harst D, Goulmy E, Falkenburg J, et al: Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 1994, 83:1060. Further evidence that differences in minor histocompatibility antigens between donor and recipient can induce an immune response that could be translated into GVHD, graft-versus-leukemia, or graft rejection.
28. Verfaillie CM, Miller WJ, Boylan K, McGlave PB: Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 1992, 79:1003.
29. Chen W, Peace D, Rovira D, You S, Cheever M: T-cell immunity to the joining region of p210 BCR-ABL protein. Proc Natl Acad Sci U S A 1992, 89:1468.
30. +.
31. Falkenburg J, Goselink van der Harst D, et al.: Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T-lymphocytes. J Exp Med 1991, 174:27.
32. Faber L, van Luxemburg-Heijs S, Willemze R, et al.: Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 1992, 176:1283.
33. van Lochem E, de Gast B, Goulmy E: In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant 1992, 10:181.
34. Hoffmann T, Theobald M, Bunjes D, et al.: Frequency of bone marrow T cells responding to HLA-identical non-leukemic and leukemic stimulator cells. Bone Marrow Transplant 1993, 12:1.
35. Hercend T, Takvorian T, Nowill A, et al.: Characterization of natural killer cells with anti-leukemia activity following allogeneic bone marrow transplantation. Blood 1986, 67:301.
36. Jiang Y, Cullis J, Kanfer E, Goldman J, Barrett A: T cell and NK cell mediated graft-versus-leukemia reactivity following donor buffy coat infusion to treat relapse after marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1993, 11:133.
37. Steinman R: The dendritic cell system and its role in immunogenicity. Ann Rev Immunol 1991, 9:271.
38. Perreault C, Pelletier M, Landry D, et al.: Study of Langerhans cells after allogeneic bone marrow transplantation. Blood 1984, 63:807.
39. Perreault C, Pelletier M, Belanger R, et al.: Persistence of host Langerhans cells following allogeneic bone marrow transplantation: possible relationship with acute graft-versus-host disease. Br J Haematol 1985,60:253.
40. Guinan E, Gribben J, Boussiotis V, Freeman G, Nadler L: Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994, 84:3261. An excellent review. Demonstrates the potential relevance of these pathways in disease and tumor immunity, as well as potential clinical applications.
41. Blazer B, Taylor P, Panoskaltsis-Mortari A, Gray G, Vallera D: Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood 1995, 85:2607. Demonstrates the importance of adhesion molecules and co-stimulatory pathways in the pathogenesis of GVHD; their role in GVL has not been as well described.
42. Hauch M, Gazzola M, Small T, et al.: Antileukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990, 75:2250.
43. Russell J: Internal disintegration model of cytotoxic lymphocyte-mediated killing, Immunol Rev 1983, 72:97.
44. Ju S: Distinct pathways of CD4 and CD8 cells induce rapid target DNA fragmentation. J Immunol 1991, 146:812.
45. + T-cell mediated cytotoxicity. J Immunol 1994, 152:1127.
46. Jadus M, Wepsic H: The roles of cytokines in graft versus host reactions and disease. Bone Marrow Transplant 1992, 10:1.
47. Antin J, Ferrara J: Cytokine dysregulation and acute graft versus host disease. Blood 1992, 80:2964.
48. Collins R, Shpilberg O, Drobyski W, et al.: Donor leukocyte infusion for post-bone marrow transplant relapse: retrospective cohort analysis of 141 cases [abstract]. Blood 1995, 86:563a.
49. Radich J, Gehly G, Gooley T, et al.: Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995, 85:2632.
50. Arthur C, Apperley J, Guo A, Rassool F, Gao L, Goldman J: Cytogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase. Blood 1988, 71:1179.
51. Bernasconi P, Alessandrino E, Caldera D, et al.: Intensive chemotherapy followed by donor PBSC in ANLL relapsed after allogeneic BMT. Bone Marrow Transplant 1995, 15:643.
52. Vesole D, Tricot G, Jagannath S, Barlogie B: Induction of graft versus myeloma (GVM) effect following allogeneic bone marrow transplantation [abstract]. Blood 1994, 84:331 a.
53. Rondón G, Khouri I, Giralt S, Huh Y, Andreeff M, Champlin R: Chimerism following sex-mismatched allogeneic BMT in chronic lymphocytic leukemia [abstract]. Blood 1994, 84:208a.
54. Papadopoulos E, Ladanyi M, Emanuel D, et al.: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994, 330:1185. Another rare but important indication for donor lymphocyte infusions after BMT.
55. Walter E, Greenberg P, Gilbert M, et al.: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995, 333:1038. Demonstrates that cytomegalovirus-specific donor lymphocytes can be cloned and infused without significant toxicity. Preliminary results also reveal that these cells can mediate an antiviral response and therefore be effective in prophylaxis.
56. Holler E, et al.: Increased levels of TNF-α precede major complications of bone marrow transplantation. Blood 1990, 75:1011.
57. Remberger M, Ringden O, Markling L: TNF-α levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant 1995, 15:99.
58. Sullivan K, Storb R, Buckner C, et al.: Graft versus host disease as adoptive immunotherapy in patients with advanced hematologic malignancies. N Engl J Med 1989, 320:828.
59. Johnson B, Truitt R: Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 1995, 85:3302.
60. Bonini C, Verzeletti S, Servida P, et al.: Transfer of the HSV-TK gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity after allo-BMT. Blood 1994, 84:110a.
61. Giralt S, O'Brien S, Talpaz M, et al.: Alpha interferon and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation. Cytokines and Molecular Therapy 1996, in press.